MedTrace Logo

Immune Suppression Of Infants Treated With Steroids

NCT00433940 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 16

Last updated 2013-01-24

No results posted yet for this study

Summary

The goal of this study is to clarify the degree of immune suppression in infants requiring therapy and to create guidelines for evaluation and prevention of infection in infants on oral steroids for hemangiomas.

Conditions

  • Hemangioma

Interventions

DRUG

Prednisolone

Oral prednisolone sodium phosphate suspension administered in dosage of 15mg/5mL. Medication administered every morning at a starting daily dose of 2.5mg/kg.

Sponsors & Collaborators

  • Medical College of Wisconsin

    lead OTHER

Principal Investigators

  • Beth A Drolet, MD · Medical College of Wisconsin

Eligibility

Max Age
6 Months
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-10-31
Primary Completion
2008-04-30
Completion
2010-07-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00433940 on ClinicalTrials.gov